References
- Vincent A, Herman J, Schulick R, Hruban RH, Goggin M. Pancreatic cancer. Lancet378, 607–620 (2011).
- Tempero MA, Berlin J, Ducreux M et al. Pancreatic cancer treatment and research: an international expert panel discussion. Ann. Oncol.22, 1500–1506 (2011).
- Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J. Clin.61, 212–236 (2011).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61, 69–90 (2011).
- O’Neill CB, Atoira CL, O’Reilly EM, LaFemina J, Elkin EB. Costs and trends in pancreatic cancer treatment: a population-based analysis. J. Clin. Oncol.29 (2011) (Abstract 6015).
- Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev.38, 351–376 (2002).
- Zagon IS, Hytrek SD, Smith JP, McLaughlin PJ. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett.112, 167–175 (1997).
- Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int. J. Oncol.14, 577–584 (1999).
- Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int. J. Oncol.33, 317–323 (2008).
- Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor–opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am. J. Physiol.297, R1154–R1161 (2009).
- Smith JP, Conter RL, Bingaman SI et al. Treatment of advanced pancreatic cancer with opioid growth factor: Phase 1. Anticancer Drugs15, 203–209 (2004).
- Smith JP, Bingaman SI, Mauger DT, Harvey HA, Demers LM, Zagon IS. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J. Clin. Trials2, 37–48 (2010).
- Fukushima N, Sato N, Ueki T et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol.160, 1573–1581 (2002).
- Ueki T, Toyota M, Sohn T et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res.60, 1835–1839 (2000).
- Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF–OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell20, 319–327 (2009).
- Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF–OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol. Cancer7, 5–17 (2008).
- Ueki T, Toyota M, Skinner H et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res.61, 8540–8546 (2001).
- Yoshikawa K, Williams C, Sabol SL. Rat brain preproenkephalin mRNA. J. Biol. Chem.259, 14301–14308 (1984).
- Smith JP, Conter R, Demers LM, McLaughlin PJ, Zagon IS. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas21, 158–164 (2000).
- Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-duPree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother. Pharmacol.56, 510–520 (2005).